These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 29404792)

  • 1. Intrathecal Drug Delivery and Spinal Cord Stimulation for the Treatment of Cancer Pain.
    Xing F; Yong RJ; Kaye AD; Urman RD
    Curr Pain Headache Rep; 2018 Feb; 22(2):11. PubMed ID: 29404792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intrathecal Therapy for Chronic Pain: A Review of Morphine and Ziconotide as Firstline Options.
    Deer TR; Pope JE; Hanes MC; McDowell GC
    Pain Med; 2019 Apr; 20(4):784-798. PubMed ID: 30137539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ziconotide: a new nonopioid intrathecal analgesic for the treatment of chronic pain.
    Wallace MS
    Expert Rev Neurother; 2006 Oct; 6(10):1423-8. PubMed ID: 17078783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intrathecal Therapy for Cancer-Related Pain.
    Bruel BM; Burton AW
    Pain Med; 2016 Dec; 17(12):2404-2421. PubMed ID: 28025375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive consensus based guidelines on intrathecal drug delivery systems in the treatment of pain caused by cancer pain.
    Deer TR; Smith HS; Burton AW; Pope JE; Doleys DM; Levy RM; Staats PS; Wallace MS; Webster LR; Rauck RL; Cousins M;
    Pain Physician; 2011; 14(3):E283-312. PubMed ID: 21587338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intrathecal therapy: what has changed with the introduction of ziconotide.
    Kress HG; Simpson KH; Marchettini P; Ver Donck A; Varrassi G
    Pain Pract; 2009; 9(5):338-47. PubMed ID: 19740270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and Safety of Intrathecal Ziconotide: Interim Analysis of the Patient Registry of Intrathecal Ziconotide Management (PRIZM).
    Deer T; Rauck RL; Kim P; Saulino MF; Wallace M; Grigsby EJ; Huang IZ; Mori F; Vanhove GF; McDowell GC
    Pain Pract; 2018 Feb; 18(2):230-238. PubMed ID: 28449352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bolus intrathecal injection of ziconotide (Prialt®) to evaluate the option of continuous administration via an implanted intrathecal drug delivery (ITDD) system: a pilot study.
    Mohammed SI; Eldabe S; Simpson KH; Brookes M; Madzinga G; Gulve A; Baranidharan G; Radford H; Crowther T; Buchser E; Perruchoud C; Batterham AM
    Neuromodulation; 2013; 16(6):576-81; discussion 582. PubMed ID: 23205907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intrathecal Pharmacology Update: Novel Dosing Strategy for Intrathecal Monotherapy Ziconotide on Efficacy and Sustainability.
    Pope JE; Deer TR
    Neuromodulation; 2015 Jul; 18(5):414-20. PubMed ID: 25708382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrathecal therapy with ziconotide: clinical experience and considerations on its use.
    Vitale V; Battelli D; Gasperoni E; Monachese N
    Minerva Anestesiol; 2008 Dec; 74(12):727-33. PubMed ID: 19034250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intrathecal Ziconotide: Dosing and Administration Strategies in Patients With Refractory Chronic Pain.
    McDowell GC; Pope JE
    Neuromodulation; 2016 Jul; 19(5):522-32. PubMed ID: 26856969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ziconotide: new drug. Limited analgesic efficacy, too many adverse effects.
    Prescrire Int; 2008 Oct; 17(97):179-82. PubMed ID: 19530373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ziconotide, an intrathecally administered N-type calcium channel antagonist for the treatment of chronic pain.
    Wermeling DP
    Pharmacotherapy; 2005 Aug; 25(8):1084-94. PubMed ID: 16207099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Considerations and methodology for trialing ziconotide.
    Burton AW; Deer TR; Wallace MS; Rauck RL; Grigsby E
    Pain Physician; 2010; 13(1):23-33. PubMed ID: 20119460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perioperative Management of a Patient With an Intrathecal Drug Delivery Device Infusing Ziconotide: A Case Report.
    Patel S; Hafez O; Sexton WJ; Edwards DA
    A A Case Rep; 2017 Feb; 8(4):78-80. PubMed ID: 28195861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intrathecal pain pumps: indications, patient selection, techniques, and outcomes.
    Bolash R; Mekhail N
    Neurosurg Clin N Am; 2014 Oct; 25(4):735-42. PubMed ID: 25240660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Ziconotide: an innovative alternative for intense chronic neuropathic pain].
    Valía-Vera JC; Villanueva VL; Asensio-Samper JM; López-Alarcón MD; de Andrés JA
    Rev Neurol; 2007 Dec 1-15; 45(11):665-9. PubMed ID: 18050098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intrathecal Drug Delivery.
    De Andrés J; Rubio-Haro R; De Andres-Serrano C; Asensio-Samper JM; Fabregat-Cid G
    Methods Mol Biol; 2020; 2059():75-108. PubMed ID: 31435916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intrathecal Pain Therapy for the Management of Chronic Noncancer Pain.
    Sukul VV
    Neurosurg Clin N Am; 2019 Apr; 30(2):195-201. PubMed ID: 30898270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ziconotide Trialing by Intrathecal Bolus Injections: An Open-Label Non-Randomized Clinical Trial in Postoperative/Posttraumatic Neuropathic Pain Patients Refractory to Conventional Treatment.
    Bäckryd E; Sörensen J; Gerdle B
    Neuromodulation; 2015 Jul; 18(5):404-13. PubMed ID: 25879804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.